Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma, Figure 2.
Rollins, M. R., Raynor, J. F., Miller, E. A., Butler, J. Z., Spartz, E. J., Lahr, W. S., You, Y., Burrack, A. L., Moriarity, B. S., Webber, B. R., & Stromnes, I. M. 2023. Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications, 14(1), 528. https://doi.org/10.1038/s41467-023-36180-1
Burrack, A.L., Spartz, E.J., Rollins, M.R., Miller, E.A., Firulyova, M., Cruz, E., Goldberg, M.F., Wang, I.X., Nanda, H., Shen, S., Zaitsev, K., Stromnes, I.M. 2022. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate. Cancer Immunology, Immunotherapy, pp.1-18. https://doi.org/10.1007/s00262-022-03338-7
Burrack, A. L., Schmiechen, Z. C., Patterson, M. T., Miller, E. A., Spartz, E. J., Rollins, M. R., Raynor, J. F., Mitchell, J. S., Kaisho, T., Fife, B. T., & Stromnes, I. M. 2022. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. JCI Insight, 7(7). https://doi.org/10.1172/jci.insight.151593
Stromnes, I.M., Hulbert, A., Rollins, M.R., Basom, R.S., Delrow, J., Bonson, P., Burrack, A.L., Hingorani, S.R. and Greenberg, P.D., 2022. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Journal for Immunotherapy of Cancer, 10(2). http://dx.doi.org/10.1136/jitc-2021-003525
Burrack, AB, Rollins, M, Spartz, EH, Mesojednik, TD, Schmiechen, ZC, Wang, IX, Raynor, JF, Kedl, R, and Stromnes IM. CD40 agonist overcomes T cell exhaustion induced by chronic myeloid cell IL-27 production in a pancreatic cancer preclinical model. Journal of Immunology, 2021 https://www.jimmunol.org/content/206/6/1372
Schmiechen, ZC. and Stromnes, IM. Mechanisms governing immunotherapy resistance in pancreatic ductal adenocarcinoma. Frontiers in Immunology, 2021 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876239/
Rollins, M, Spartz, EH, and Stromnes IM. T cell receptor engineered lymphocytes for adoptive cell therapy. Current Protocols in Immunology. V 129 (1):e97, 2020 https://currentprotocols.onlinelibrary.wiley.com/doi/full/10.1002/cpim.97
Burrack, AB, Spartz, EH, Raynor, JF, Wang, Iris, Olson, M and Stromnes IM. Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma. Cell Reports, 2019 https://pubmed.ncbi.nlm.nih.gov/31433988/
Anderson, KG, Voillet, V, Bates, BM, Chiu, EY, Burnett, MG, Garcia, N, Oda, S, Morse, CB, Stromnes, I., Drescher, CW, Gottardo, R and Greenberg, P. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunology Research, 2019 https://cancerimmunolres.aacrjournals.org/content/7/9/1412
Stromnes IM, Burrack A, Hulbert A, Black C, Bonson P, Raynor J, Spartz, E, Pierce RH, Hingorani SR and Greenberg PD. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunology Research 2019, https://pubmed.ncbi.nlm.nih.gov/31028033/
Stromnes, IM et al., T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research, 2017 https://www.ncbi.nlm.nih.gov/pubmed/29066497
Anderson KA, Stromnes IM and Greenberg, PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell, 2017 https://www.ncbi.nlm.nih.gov/pubmed/28292435
Stromnes, IM and Greenberg, PD. Pancreatic Cancer: Planning Ahead for Metastatic Spread. Cancer Cell, 2016 https://www.ncbi.nlm.nih.gov/pubmed/27300430
Stromnes IM et al., T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26525103
Stromnes IM et al. Molecular Pathways: Myeloid complicity in cancer. Clinical Cancer Research. https://www.ncbi.nlm.nih.gov/pubmed/25047706
Stromnes IM et al., Stromal reengineering to treat pancreas cancer. Carcinogenesis, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24908682
Stromnes IM et al, Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24555999
Stromnes IM et al., Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunology Reviews, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24329795
Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood, The Journal of the American Society of Hematology. 2013 Â https://www.ncbi.nlm.nih.gov/pubmed/23673862